Baicalin and deferoxamine alleviate iron accumulation in different brain regions of Parkinson’s disease rats

Neural Regeneration Research

Volumn 7, Issue 27, 2012, Pages 2092-2098

  Xiong, Pei ^a   Chen, Xin ^a   Guo, Chun Yan ^a   Zhang, Nan ^a   Ma, Bao Cang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Baicalin; Cerebellum; Deferoxamine; Hippocampus; Iron; Neural regeneration; Neurodegenerative disease; Parkinson s disease; Regeneration; Rotenone; Striatum; Substantia nigra

Indexed keywords

EID: 84916629255     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2012.27.002     Document Type: Article

References (35)

1. [1] Rouault TA. Iron on the brain. Nature Genetics. 2001; 28(4):299-300.
2. [2] Gotz ME, Double K, Gerlach M, et al. The relevance of iron in the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci. 2004;1012:193-208.
3. [3] Gorell JM, Ordidge RJ, Brown GG, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology. 1995;45(6):1138-1143.
4. [4] Michaeli S, Oz G, Sorce DJ, et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disorder. 2007; 22(3):334-340.
5. [5] Martin WRW, Wieler M, Gee M. Midbrain iron content in early Parkinson disease-A potential biomarker of disease status. Neurology. 2008;70(16 Pt 2):1411-1417.
6. [6] Ryvlin P, Broussolle E, Piollet H, et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol. 1995;52(6):583-588.
7. [7] Ye FQ, Allen PS, Martin WR. Basal ganglia iron content in Parkinson’s disease measured with magnetic resonance. Mov Disord. 1996;11(3):243-249.
8. [8] Berrshachar D, Youdim MB. Intranigral iron injection induces behavioral and biochemical “Parkinsonism” in rats. J Neurochem. 1991;57(6):2133-2135.
9. [9] Zecca L, Youdim MB, Riederer P, et al. Iron, brain aging and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863-873.
10. [10] Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging. 2005;23(1):1-25.
11. [11] Oakley R, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology. 2007;68(21):1820-1825.
12. [12] Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol. 2001;248(8):684-689.
13. [13] Walter U, Wittstock M, Benecke R, et al. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm. 2002;109(2):191-196.
14. [14] Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson’s disease: Implications for idiopathic and monogenetic forms. Neurochem Res. 2007;32(10):1646-1654.
15. [15] Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord. 2005;20(10):1278-1285.
16. [16] Miao YW, Wu JL. MR progress on excessive iron deposition in chronic nervous diseases. Zhongguo Yixue Yingxiangxue Jishu. 2009;25(11):2129-2131.
17. [17] Yang H, Cao XB. The recent development of the correlation research of iron and Parkinson’s disease. Guowai Yixue: Shenjingbingxue Jingshenwaikexue Fence. 2000;27(4):180-183.
18. [18] Wang J. The development of MRI detection brain iron content of neurodegenerative diseases. Linchuang Fashexue Zazhi. 2003;22(7):600-602.
19. [19] Song YW, Chen X, Zhang N, et al. Inhibition on iron deposition in SN in PD rats by baicalin and its mechanism. Zhongguo Yaolixue Tongbao. 2011;27(12):1740-1744.
20. [20] Chen X, Zhang N, Zhao H, et al. The protect effect of Baicalin on the substantial nigra dopaminergic neuron in Parkinson’s rats induced by rotenone. Zhongfeng yu Shenjing Jibing. 2008;25(2):174-177.
21. [21] Guo CY, Chen X. Baicalin interferes with iron accumulation in C6 glioma cells. Neural Regen Res. 2011;6(30):2352-2356.
22. [22] Dobson J. Nanoscale biogenic iron oxides and neurodegenerative disease. FEBS Lett. 2001;496(1):1-5.
23. [23] Jiang H, Qian ZM, Xie JX. Increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice. Shengli Xuebao. 2003;55(5):571-576.
24. [24] Wang FB, Ding HL, Wang WG, et al. The effects of microinjection of ethanol into dorso medial area of nucleus facialis on the genioglossal muscle and phrenic muscle activities. Weifang Yixueyuan Xuebao. 1999;21(3): 183-184.
25. [25] Wang L, Liu L, Xu X. Effects of stimulation of dorsal medial area and ventral medial are of nucleus facials on myoelectric activities of genioglossus and phrenic muscle. Acta Physiological Sinica. 1999;51(4):439-444.
26. [26] Lavond DG, Hembree TL, Thompson RF. Effect of kainic acid lesions of the cerebellar interpositusnucleus on eyelid conditioning in the rabbit. Brain Res. 1985;326(1): 179-182.
27. [27] Krupa D J, Thompson JK, Thompson RF. Localization ofamemory trace in the mammalian brain. Science. 1993; 260(5110):989-991.
28. [28] Yu QX, Gao JF, Wang JJ, et al. Hippocampus-cerebellar cortex-cerebellar nuclei projection in the rat: electrophysiological and HRP studies. Acta Physiological Sinica. 1989;41(3):231.
29. [29] Lin H. A study on neurobiological mechanism of repetitive transcranial magnetic stimulation in treating neuropsychiatry disorders. Shaanxi: The Fourth Military Medical University. 2001.
30. [30] Xiao L, Zhang XJ, Wang F, et al. Distribution of baicalin in Qingkailing injection in the brain, Lung and liver of both normal and ischemia-reperfusion rats. Zhongnan Yaoxue. 2006;4(3):166-167.
31. [31] The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
32. [32] Chen X, Zhang N, Mu RY. The protective effect of baicalin against the degeneration of nigral dopaminergic neurons and lesion of the mesencephalon induced by FeCl3 in rats. Shizhen Guoyi Guoyao. 2010;21(1):64-66.
33. [33] He DF, Zhang B, Wang J, et al. The neurotoxic effect of chronically exposion of retenone and pyridaben. Zhongguo Laonianxue Zazhi. 2005;25(9):1099-1101.
34. [34] Dong CY. The effect of rotenone on the dopaminergic neurons in snc of rats and its effect combined with iron. Shanghai: East China Normal University. 2008.
35. [35] Chen X, Zhang N, Zhao H, et al. The relations of behavioral features and loss of Nigrostriatum on the model of Parkinson’s disease induced by rotenone on rats. Zhongguo Jingshen Shenjing Zazhi. 2008;34(4):232-234.